BARINTHUS BIOTHERAPEUTICS PLC
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $15.0M | $802.0K | $44.7M | $268.0K | $4.8M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $25.6M | $42.2M | $44.9M | $42.4M | $20.4M | $14.4M |
| SG&A Expense | $40.8M | $29.7M | $39.8M | $6.4M | $25.1M | $10.5M |
| Operating Income | $-70.6M | $-68.0M | $-83.9M | $-4.0M | $-45.2M | $-20.0M |
| Operating Margin | — | -454.1% | -10,463.1% | -9.0% | -16,873.5% | -415.8% |
| Interest Expense | — | — | $28.0K | $19.0K | $2.7M | $3.6M |
| Pretax Income | $-66.6M | $-61.2M | $-76.5M | $850.0K | $-51.1M | — |
| Income Tax Expense | $-175.0K | $-44.0K | $-3.1M | $-4.5M | $-28.0K | $95.0K |
| Net Income | $-66.4M | $-61.1M | $-73.3M | $5.3M | $-50.9M | $-17.7M |
| Net Margin | — | -408.0% | -9,145.5% | 11.9% | -18,979.5% | -367.3% |
| EPS (Basic) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-0.75 |
| EPS (Diluted) | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-0.75 |
| Shares Outstanding (Basic) | 40.5M | 39.3M | 38.4M | 37.2M | 25.9M | 23.7M |
| Shares Outstanding (Diluted) | 40.5M | 39.3M | 38.4M | 38.2M | 25.9M | 23.7M |
| Dividends Per Share | — | — | — | — | — | — |